Trial Profile
A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients With Small Cell Lung Cancer (SCLC) or Other Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Palcitoclax (Primary)
- Indications Brain metastases; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Ascentage Pharma
- 28 Aug 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results (N=42), of dose-escalation phase, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results published in the Ascentage Pharma Media Release.